Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA-yW synthesizing protein 1 homolog (TYW1) is an enzyme that participates in the post-transcriptional modification of tRNA, specifically in the biosynthesis of wybutosine (yW)—a highly modified guanosine derivative at position 37 of eukaryotic phenylalanine tRNA[1][4][5][7]. This modification is critical for maintaining translational fidelity by stabilizing codon-anticodon pairing during protein synthesis[1]. TYW1 is a member of the radical S-adenosylmethionine (SAM) superfamily and contains an iron-sulfur (4Fe-4S) cluster essential for its catalytic activity[4][5]. It catalyzes the second step of wybutosine biosynthesis, converting N^1^-methylguanosine (m^1^G) at position 37 of tRNA^Phe^ into the tricyclic base 4-demethylwyosine (imG-14) using carbons derived from pyruvate[4][5][7]. The human gene TYW1 has several transcript variants due to alternative splicing and shares homology with the yeast TYW1 gene[1]. While not currently a primary therapeutic or drug target, mutations or dysregulation in TYW1 is associated with diseases such as Shwachman-Diamond syndrome 1 and spastic monoplegia[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA-yW synthesizing protein 1 homolog (TYW1).